Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Study of FLUTIFORM [formoterol fumarate/fluticasone propionate] vs Seratide [salmeterol/fluticasone propionate] in paediatric subjects with asthma

Trial Profile

Study of FLUTIFORM [formoterol fumarate/fluticasone propionate] vs Seratide [salmeterol/fluticasone propionate] in paediatric subjects with asthma

Completed
Phase of Trial: Phase III

Latest Information Update: 08 Nov 2018

At a glance

  • Drugs Formoterol/fluticasone propionate (Primary) ; Salmeterol/fluticasone propionate
  • Indications Asthma
  • Focus Therapeutic Use
  • Sponsors Mundipharma Research
  • Most Recent Events

    • 08 Nov 2018 According to a Mundipharma international media release, based on data from this and other paediatric study, the Mundipharma network of independent associated companies today announced that the European Decentralised Procedure (DCP) licence variation application for flutiform, extending the indication to the treatment of asthmatic children, has closed with a positive opinion.
    • 04 Jul 2012 Company added in the association field as reported by EudraCT.
    • 28 Sep 2011 Extension study tolerability results presented at the 21st Annual Congress of the European Respiratory Society.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top